Arrowstreet Capital Limited Partnership Has $258.09 Million Stock Position in Insulet Corporation $PODD

Arrowstreet Capital Limited Partnership lifted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 462.7% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,229,928 shares of the medical instruments supplier’s stock after purchasing an additional 1,011,369 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in Insulet were worth $258,088,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Insulet by 26.5% in the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock worth $12,484,000 after acquiring an additional 9,206 shares during the period. Zevenbergen Capital Investments LLC acquired a new stake in Insulet during the 4th quarter valued at approximately $32,143,000. Aberdeen Group plc raised its holdings in Insulet by 45.6% during the 4th quarter. Aberdeen Group plc now owns 225,429 shares of the medical instruments supplier’s stock worth $64,076,000 after purchasing an additional 70,607 shares during the last quarter. Asset Management One Co. Ltd. raised its holdings in Insulet by 99.5% during the 4th quarter. Asset Management One Co. Ltd. now owns 76,594 shares of the medical instruments supplier’s stock worth $21,948,000 after purchasing an additional 38,193 shares during the last quarter. Finally, OP Asset Management Ltd acquired a new position in shares of Insulet in the 1st quarter worth approximately $1,513,000.

Insulet Price Performance

Shares of NASDAQ PODD opened at $163.26 on Friday. The firm’s 50-day moving average price is $154.09 and its 200-day moving average price is $202.61. The firm has a market capitalization of $11.31 billion, a P/E ratio of 37.97, a P/E/G ratio of 1.11 and a beta of 1.11. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a 1-year low of $138.79 and a 1-year high of $354.88.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter last year, the firm posted $1.02 earnings per share. The company’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts anticipate that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the completion of the purchase, the director owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

PODD has been the topic of a number of analyst reports. Wall Street Zen lowered shares of Insulet from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Jefferies Financial Group lowered their target price on shares of Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Royal Bank Of Canada dropped their target price on shares of Insulet from $280.00 to $245.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Finally, Rothschild & Co Redburn reissued a “neutral” rating and issued a $220.00 price objective (down from $380.00) on shares of Insulet in a research report on Friday, April 24th. Twenty-two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $235.25.

Key Headlines Impacting Insulet

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: No meaningful positive company-specific catalysts were reported in the latest batch of news.
• Neutral Sentiment: Short-interest data showed 0 shares reported short as of July 24, with a 0.0-day days-to-cover ratio, offering little actionable insight from that update.
• Negative Sentiment: Multiple law firms, including Rosen, Schall, Glancy Prongay, Pomerantz, Bernstein Liebhard, Faruqi & Faruqi, and others, announced or promoted securities class actions against Insulet, which can weigh on investor confidence. Article link
• Negative Sentiment: The lawsuits allege Insulet made misleading statements about manufacturing quality and safety issues, including problems at its Acton facility and flawed pods, suggesting potential reputational and legal overhang for the stock. Article link

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.